A Systematic Approach to Design and Prepare Solid Dispersions of Poorly Water-soluble Drug

Overview

Journal AAPS PharmSciTech

Publisher Springer

Specialty Pharmacology

Date 2014 Feb 25

PMID 24563175

Citations 11

Authors

Sanjay Verma

Varma S Rudraraju

Affiliations

Soon will be listed here.

Abstract

The objective of the present study was to define a systematic approach to design and prepare solid dispersions of poorly water-soluble drug. The systematic approach can be defined in four phases. In the first phase, glass forming ability is assessed, and in the second phase, probable excipients are screened. The screened excipients are evaluated (third phase) for glass transition temperatures (Tg) and miscibility studies according to Florey-Huggins interaction parameter. The predicted excipients are used to prepare the solid dispersion and evaluated for Tg and any interactions using Fourier transfer infrared studies (fourth phase), and the findings are correlated with phase three predictions. For this investigation, cilostazol (CIL) was selected as model drug, which was classified as a poor glass former. As per the physical chemical properties of CIL, ten excipients, both polymeric and non-polymeric, were selected and screened. Out of these, povidone, copovidone, hypromellose and Eudragit EPO were found theoretically miscible with CIL. After going through phase 2 to phase 4, only povidone, copovidone and hypromellose were confirmed as polymer of choice for preparing the solid dispersion of CIL with a prediction of better physical solid-state stability on the basis of good miscibility between drug and carrier.

Citing Articles

Utilizing Drug Amorphous Solid Dispersions for the Preparation of Dronedarone per os Formulations.

Kapourani A, Manioudaki A, Kontogiannopoulos K, Barmpalexis P Polymers (Basel). 2023; 15(21).

PMID: 37959973 PMC: 10649729. DOI: 10.3390/polym15214292.

Influence of Plasdone S630 Ultra-an Improved Copovidone on the Processability and Oxidative Degradation of Quetiapine Fumarate Amorphous Solid Dispersions Prepared via Hot-Melt Extrusion Technique.

Butreddy A, Sarabu S, Bandari S, Batra A, Lawal K, Chen N AAPS PharmSciTech. 2021; 22(5):196.

PMID: 34184149 PMC: 8425456. DOI: 10.1208/s12249-021-02069-9.

Hot-Melt Extrusion: a Roadmap for Product Development.

Simoes M, Pinto R, Simoes S AAPS PharmSciTech. 2021; 22(5):184.

PMID: 34142250 DOI: 10.1208/s12249-021-02017-7.

Quality-by-design in hot melt extrusion based amorphous solid dispersions: An industrial perspective on product development.

Butreddy A, Bandari S, Repka M Eur J Pharm Sci. 2020; 158:105655.

PMID: 33253883 PMC: 7855693. DOI: 10.1016/j.ejps.2020.105655.

Stabilisation and Growth of Metastable Form II of Fluconazole in Amorphous Solid Dispersions.

Nowak M, Gajda M, Baranowski P, Szymczyk P, Karolewicz B, Nartowski K Pharmaceutics. 2019; 12(1).

PMID: 31877666 PMC: 7023302. DOI: 10.3390/pharmaceutics12010012.

References

Forster A, Hempenstall J, Tucker I, Rades T . Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm. 2001; 226(1-2):147-61. DOI: 10.1016/s0378-5173(01)00801-8. View

Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M . In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release. 2008; 130(1):29-37. DOI: 10.1016/j.jconrel.2008.05.013. View

Amidon G, Lennernas H, Shah V, Crison J . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3):413-20. DOI: 10.1023/a:1016212804288. View

Yoo S, Krill S, Wang Z, Telang C . Miscibility/stability considerations in binary solid dispersion systems composed of functional excipients towards the design of multi-component amorphous systems. J Pharm Sci. 2009; 98(12):4711-23. DOI: 10.1002/jps.21779. View

Chokshi R, Sandhu H, Iyer R, Shah N, Malick A, Zia H . Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution. J Pharm Sci. 2005; 94(11):2463-74. DOI: 10.1002/jps.20385. View

Craig D, Royall P, Kett V, Hopton M . The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int J Pharm. 1999; 179(2):179-207. DOI: 10.1016/s0378-5173(98)00338-x. View

Law D, Krill S, Schmitt E, Fort J, Qiu Y, Wang W . Physicochemical considerations in the preparation of amorphous ritonavir-poly(ethylene glycol) 8000 solid dispersions. J Pharm Sci. 2001; 90(8):1015-25. DOI: 10.1002/jps.1054. View

Pajula K, Taskinen M, Lehto V, Ketolainen J, Korhonen O . Predicting the formation and stability of amorphous small molecule binary mixtures from computationally determined Flory-Huggins interaction parameter and phase diagram. Mol Pharm. 2010; 7(3):795-804. DOI: 10.1021/mp900304p. View

Hilden L, Morris K . Physics of amorphous solids. J Pharm Sci. 2003; 93(1):3-12. DOI: 10.1002/jps.10489. View

10.

Kaushal A, Bansal A . Thermodynamic behavior of glassy state of structurally related compounds. Eur J Pharm Biopharm. 2008; 69(3):1067-76. DOI: 10.1016/j.ejpb.2008.02.001. View

11.

Pinnamaneni S, Das N, Das S . Formulation approaches for orally administered poorly soluble drugs. Pharmazie. 2002; 57(5):291-300. View

12.

Stowell G, Behme R, Denton S, Pfeiffer I, Sancilio F, Whittall L . Thermally-prepared polymorphic forms of cilostazol. J Pharm Sci. 2002; 91(12):2481-8. DOI: 10.1002/jps.10240. View

13.

Money S, HERD J, Isaacsohn J, Davidson M, Cutler B, HECKMAN J . Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg. 1998; 27(2):267-74; discussion 274-5. DOI: 10.1016/s0741-5214(98)70357-x. View

14.

Graeser K, Patterson J, Zeitler J, Gordon K, Rades T . Correlating thermodynamic and kinetic parameters with amorphous stability. Eur J Pharm Sci. 2009; 37(3-4):492-8. DOI: 10.1016/j.ejps.2009.04.005. View

15.

Lin D, Huang Y . A thermal analysis method to predict the complete phase diagram of drug-polymer solid dispersions. Int J Pharm. 2010; 399(1-2):109-15. DOI: 10.1016/j.ijpharm.2010.08.013. View

16.

Tajber L, Corrigan O, Healy A . Physicochemical evaluation of PVP-thiazide diuretic interactions in co-spray-dried composites--analysis of glass transition composition relationships. Eur J Pharm Sci. 2005; 24(5):553-63. DOI: 10.1016/j.ejps.2005.01.007. View

17.

Whittall L, Whittle R, Stowell G . Polymorphic forms of cilostazol. Acta Crystallogr C. 2002; 58(Pt 8):o525-7. DOI: 10.1107/s0108270102012544. View

18.

Hu J, Johnston K, Williams 3rd R . Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev Ind Pharm. 2004; 30(3):233-45. DOI: 10.1081/ddc-120030422. View

19.

Dressman J, Amidon G, Reppas C, Shah V . Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998; 15(1):11-22. DOI: 10.1023/a:1011984216775. View

20.

Patel S, Rajput S . Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. AAPS PharmSciTech. 2009; 10(2):660-9. PMC: 2690812. DOI: 10.1208/s12249-009-9249-7. View